AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$MAIA

Guerrero Ramiro purchased $184K of MAIA

Guerrero Ramiro purchased 133,790 shares of MAIA Biotechnology, Inc. (MAIA) at an average of $1.38 ($1.35–$1.39, $0.18M total) across 3 trades over 2026-08-26 to 2026-08-28.

Original reporting
SEC EDGAR · Guerrero Ramiro
Published Sep 1, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MAIA
Bullish
medium confidence
Mentioned
$MAIA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAIABullishLow
01

Why it matters

The director's purchase may slightly boost investor sentiment but is unlikely to move the stock significantly.

02

Market read

Primary disclosure of a modest insider purchase; low trading relevance.

03

What to watch

Potential upcoming clinical trial milestones or financing needs not disclosed in the filing.

Relevance 5/10Novelty 4/10Timing: post‑market Sep 1 filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the purchase.

Company-level read

Ticker impact

$MAIABullishMedium confidence
Context

Director Guerrero Ramiro purchased 133,790 shares of MAIA at a weighted average price of $1.3761, totaling $184,103.30.

Expected impact

Potential short-term price uptick of 1‑2% as the market digests the insider buying.

Evidence & confidence

A director buying a sizable block, even at a modest dollar amount, is viewed as a positive signal, but the total value is small relative to market cap.

Market effects

Sector

Insider buying may be noted by biotech sector investors as a confidence cue.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact given the small transaction size.

Counterpoint

What could challenge this read

The purchase could be routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Company
    MAIA Biotechnology, Inc.

    Biotech firm focused on developing therapies.

  • Director
    Guerrero Ramiro

    Board member of MAIA who executed the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MAIA insider trading history →

Related articles

OCT 7
$MAIAMedAI 8/10

MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%

MAIA Biotechnology (MAIA) announced completing enrollment for Part C of its Phase 2 THIO-101 trial and 65% completion for its Phase 3 THIO-104 trial, both evaluating ateganosine in NSCLC. The company reported a 90.5% interim disease control rate for the combination therapy. MAIA aims to enroll 100 patients in THIO-104 by 2026, with an interim analysis planned for 2027. The FDA granted Fast Track designation to ateganosine in July 2025. MAIA shares are up 0.85% at $1.20.

rttnews.com2 min
OCT 7
$MAIAMedAI 9/10

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer

MAIA Biotechnology (NYSE American: MAIA) reported milestones in its Phase 2 and Phase 3 trials for ateganosine, a telomere-targeting agent for non-small cell lung cancer (NSCLC). Enrollment is complete for Part C of the Phase 2 trial, with 90.5% interim disease control reported. The Phase 3 trial has reached 65% of its 100-patient enrollment target. The FDA granted Fast Track designation to ateganosine in July 2025.

globenewswire.com2 min